Plain-English translation of NCT05856981 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new drug called , which works by helping your immune system recognize and attack cancer cells. Researchers want to find the safest dose and see how well this medication works when given by itself or combined with another immune therapy drug called . The study will enroll about 130 adults with various advanced cancers.
Many patients with advanced cancers stop responding to current immune therapies, and doctors need new treatment options. This medication is designed to work through a different pathway in the immune system, which might help patients whose cancers have become resistant to existing treatments.
You likely qualify if…
You likely don't qualify if…
You will receive infusions of the medication intravenously (through a vein) every three weeks at the study center. Depending on which group you're in, you'll receive either the new medication alone or combined with . Throughout the trial, you'll have regular blood tests and scans to monitor how you're responding and to check for any side effects. The study has two phases: first, researchers find the safest dose, and then they test that dose in larger groups of patients with specific cancer types.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
United States
Belgium